Abstract
Secondary loss of response (LoR) often precludes further use of infliximab in children with Crohn s disease. Immunomodulators may reduce the incidence of LoR but their combination with infliximab presents safety concerns. We aimed to determine the long-term durability of infliximab response in paediatric Crohn s, effect of immunomodulators on LoR, and secondarily the effect of infliximab on growth.
Original language | English |
---|---|
Pages (from-to) | 1322-1334 |
Number of pages | 13 |
Journal | Pharmaceuticals |
Volume | 6 |
DOIs | |
Publication status | Published - 2013 |